Compared with bare-metal stents (BMS), drug-eluting stents (DES) improve clinical and angiographic outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) (1, 2) . Although favorable results may be achieved with PCI in complex lesions (3) (4) (5) (6) , patients with moderately and severely calcified lesions have been excluded from enrollment in most stent trials and still represent a challenge even in the DES era. Coronary calcification may impair stent delivery and expansion and damage the polymer/ drug coating, resulting in impaired drug delivery and predisposition to restenosis and stent thrombosis (7) . Whereas small studies in the BMS era demonstrated reduced eventfree survival after PCI of calcified compared with noncalcified lesions, surprisingly little is known about the effect of coronary calcification on outcomes after PCI with DES (8) (9) (10) (11) (12) . Moreover, no studies have evaluated the frequency and impact of coronary calcification in patients presenting with non-ST-segment elevation acute coronary syndromes (NSTEACS) and ST-segment elevation myocardial infarction (STEMI). We therefore sought to determine the frequency and impact of target lesion coronary calcification on clinical events in patients in whom PCI was performed in the setting of NSTEACS or STEMI in a pooled analysis from the large-scale ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trials (13, 14) .
Methods
Study designs and patients. The ACUITY and HORIZONS-AMI trial designs and results have previously been described in detail (13) (14) (15) (16) . In brief, ACUITY was a multicenter, prospective, randomized trial of 13,819 patients with moderate-and high-risk NSTEACS who were treated with an early invasive strategy. Prior to coronary angiography, patients were randomly assigned to heparin (unfractionated or low-molecular-weight) plus a glycoprotein IIb/ IIIa inhibitor (GPI), bivalirudin plus a GPI, or bivalirudin monotherapy. Angiography was performed within 72 h of randomization, and depending on coronary anatomy, patients were triaged to PCI, coronary artery bypass graft (CABG) surgery, or medical therapy. In patients undergoing PCI, stent choice (BMS or DES) was per operator discretion. Dual antiplatelet therapy with aspirin and clopidogrel was recommended for at least 1 year. In HORIZONS-AMI, 3,602 patients with STEMI presenting within 12 h of symptom onset were randomly assigned to unfractionated heparin plus GPI or bivalirudin monotherapy. Immediate coronary angiography was performed after randomization, followed by PCI, CABG, or medical management at physician discretion. Eligible patients were randomized again (3:1) to receive paclitaxel-eluting stents (Boston Scientific, Natick, Massachusetts) or otherwise identical BMS (Boston Scientific). Aspirin and clopidogrel were administered before catheterization; aspirin was continued indefinitely and clopidogrel for at least 1 year (14, 16) . Patients with severe renal insufficiency (calculated creatinine clearance <30 ml/min) were not included in either trial.
Patients in whom qualitative and quantitative coronary angiography (QCA) was performed comprised the present study population. QCA was performed at the Cardiovascular Research Foundation (New York, New York) by technicians blinded to randomization and outcomes in all patients in the HORIZONS-AMI trial and in those enrolled in the formal ACUITY angiographic substudy, as previously described (17) . Interobserver and intraobserver QCA core laboratory variability kappa values (50 coronary angiograms assessed twice [8 weeks apart] by 12 angiographic core laboratory technicians) for the degree of target lesion calcification were 0.83 and 0.89, respectively, representing excellent agreement. Independent clinical events committees, blinded to treatment assignment, adjudicated all major adverse events in both trials. Objectives and angiographic analysis. The primary study objective was to assess the relationship between the presence and extent of target lesion coronary calcification and the 1-year rate of ischemic events, including death, cardiac death, reinfarction, definite stent thrombosis, and ischemic target lesion revascularization (TLR) and target vessel revascularization. For the present report, we limited our analyses to the patients with STEMI in whom PCI was performed in the HORIZONS-AMI trial and to the patients with NSTEACS in whom PCI was performed in the formal angiographic substudy from ACUITY (17) . Endpoint definitions and statistical analysis. The ACUITY and HORIZONS databases were combined, and patients from this pooled population were stratified on the basis of severity of coronary artery calcification (none/mild, moderate, and severe). The pre-specified angiographic core laboratory definition of moderate calcification was radiopaque densities noted only during the cardiac cycle and typically involving only one side of the vascular wall. Severe calcification was defined as radiopaque densities noted without Daiichi Sankyo; and is a shareholder in Endothelix. Dr. Stone has served as a consultant for Boston Scientific and Cardiovascular Systems, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The first 2 authors contributed equally to this paper.
Manuscript received June 19, 2013; revised manuscript received January 5, 2014, accepted January 6, 2014. Coronary Calcification and Percutaneous Coronary Intervention May 13, :1845 cardiac motion prior to contrast injection and generally involving both sides of the arterial wall (18) . Major adverse cardiovascular events (MACE) were defined as the composite of death, reinfarction, and unplanned revascularization for ischemia. The specific definitions of the components of MACE have been previously described (13, 14) .
See page 1855
Categorical data were compared by the chi-square test or Fisher exact test if the expected number of observations in any cell was <5. Continuous data are presented as mean AE SD or median AE interquartile range and were compared using the analysis of variance or Kruskal-Wallis test as appropriate. The 30-day event rates were estimated using Kaplan-Meier time-to-event methodology and were compared using the log-rank test. Multivariable regression analysis using Cox proportional hazards models to assess for independent predictors for the presence of target lesion coronary artery calcification and for the association between the presence of coronary calcification and 1-year ischemic outcomes were performed with variable entry/stay criteria of 0.1/0.1. Variables included into the model were carefully selected to avoid overfitting of the model. Because of the relatively small number of patients with severe coronary calcification, the moderate and severe target lesion calcification groups were pooled for these analyses. Values of p < 0.05 were considered to be statistically significant, and all p values are 2-sided. Statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, North Carolina).
Results
From the angiographic substudy of ACUITY (NSTEACS) and HORIZONS-AMI (STEMI), 3,587 and 3,268 patients, respectively, undergoing PCI were pooled, for a total of 6,855 patients comprising the study population. A total of 8,381 target lesions were present, of which 451 (5.4%), 2,138 (25.5%), and 5,792 (69.1%) were assessed by the angiographic core laboratory as heavily calcified, moderately calcified, and none/mildly calcified, respectively. Target lesion calcification was severe in 402 patients (5.9%) in whom PCI was performed in 550 total lesions; moderate in 1,788 patients (26.1%) in whom PCI was performed in 2,430 total lesions; and none/mild in 4,665 patients (68.1%) in whom PCI was Values are median (interquartile range) or n/N (%). Hypertension is defined as previous diagnosis of hypertension and on antihypertensive medication on admission. Hyperlipidemia is defined as previous diagnosis of hyperlipidemia and on lipid-lowering medication on admission. Renal insufficiency is defined as a calculated creatinine clearance rate <60 ml/min by the Cockcroft-Gault equation. CABG ¼ coronary artery bypass graft; NSTEMI ¼ non-ST-segment elevation myocardial infarction; PCI = percutaneous coronary intervention; STEMI = STsegment elevation myocardial infarction; WBC = white blood cells. Généreux et al.
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Coronary Calcification and Percutaneous Coronary Intervention performed in 5,829 total lesions. A total of 54 patients had both moderately and severely calcified lesions. Patient characteristics, angiographic findings, and treatment randomization. As shown in Table 1 and Online Table 1 , compared with patients without calcified lesions, patients with more extensive target lesion calcification were more likely to be older, have renal insufficiency, lower left ventricular ejection fraction, and higher white blood cell count at baseline and more frequently had undergone prior PCI. Target lesion calcification was more frequent among the STEMI population 54 than in the NSTEACS population. By multivariable analysis, advanced age, male sex, history of hypertension, and STEMI presentation were independent predictors of moderate/severe target lesion calcification (Table 2) .
Compared with those without calcification, moderately and severely calcified lesions were longer, were more often total occlusions and bifurcations, and were more likely to contain thrombi (Table 3, Online Table 2 ). Patients with moderate and severe target lesion calcification also had more extensive coronary disease, requiring a greater number of stents implanted. A similar proportion of DES were used in all groups. Patients with greater target lesion calcification were more likely to have suboptimal angiographic results after PCI, with higher residual stenosis, more slow flow, no reflow, dissection, and abrupt closure. Clinical outcomes. As shown in Table 4 (Table 5 ).
Discussion
The current report, drawn from a cohort of 6,855 patients undergoing PCI for ACS (NSTEACS and STEMI) is by far the largest study to date to specifically evaluate the incidence, predictors, and impact of target lesion calcification on prognosis after stent implantation in this high-risk patient population. The main results of the present study were as follows: 1) target lesions in NSTEACS and STEMI were frequently calcified, as assessed by an angiographic core laboratory; 2) PCI in patients with moderately and severely calcified target lesions compared with those with no or mild calcification was associated with suboptimal angiographic results and procedural complications; and 3) PCI of calcified lesions was independently predictive of adverse ischemic outcomes, including definite stent thrombosis and unplanned ischemiadriven repeat revascularization within 1 year post-PCI, as compared with patients in whom all target lesions had no or only mild calcification. Table 3 .
Figure 1 Adverse Outcomes Through 1 Year According to Severity of Target Lesion Calcification
Comparison of the cumulative event rates through 1 year in patients stratified by no to mildly, moderately, and severely calcified target lesions. Rates of death, cardiac death, definite stent thrombosis (ST), ischemia-driven target revascularization, and major adverse cardiovascular events (MACE) all demonstrated significant overall trends between the calcification groups. MI ¼ myocardial infarction; TLR ¼ target lesion revascularization.
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Lesions responsible for ACS are typically considered to be soft, lipid rich, friable, and not calcified (19) . Contrary to these expectations, by commonly accepted core laboratory angiographic criteria, moderately or severely calcified coronary lesions were surprisingly frequent in the present study. Indeed, approximately 27% of patients with NSTEACS and 38% of patients with STEMI had one or more moderately/ severely calcified target lesions requiring PCI. Most prior randomized DES trials (1) (2) (3) (4) (5) (20) (21) (22) (23) (24) (25) (26) excluded patients with operator-assessed moderate or severe target lesion calcification. Nonetheless, 29.4% of the treated lesions in the ACUITY and HORIZONS-AMI trials were moderately or severely calcified as assessed by an independent angiographic core laboratory, evidence that interventional cardiologists underestimate the severity of calcification. Other contemporary DES studies in which a "real-world" population was enrolled have also reported high rates of target lesion calcification. In the COMPARE (Comparison of the Everolimus-Eluting XIENCE-V Stent With the Paclitaxel-Eluting TAXUS LIBERTÉ Stent in All-Comers) trial, in which 59.7% of 1,800 enrolled patients had ACS, 33.3% of lesions were reported to be calcified (27) .
Previous small to moderately sized studies, mostly from the BMS era, reported higher rates of peri-procedural complications and/or restenosis after PCI of calcified lesions (10) (11) (12) 28) . Surprisingly few reports, however, have commented on the safety and efficacy of DES treatment of calcified lesions. In the largest prior study of 1,537 patients undergoing PCI of moderately/severely calcified lesions (653 of whom received DES by operator preference), DES use was associated with lower rates of adverse ischemic outcomes than BMS (12) . No prior study has examined the impact of target lesion calcification specifically in a high-risk ACS population, in whom 1-year rates of cardiac death and stent thrombosis are increased. The present large-scale study of 6,855 patients with ACS undergoing PCI, approximately 80% of whom were treated with DES, demonstrated that treatment of calcified target lesions remains a strong Généreux et al.
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predictor for adverse safety and efficacy outcomes in the contemporary PCI era. After adjustment for imbalances in measured confounders, treatment of calcified target lesions compared with no calcification was independently associated with a 62% increase in stent thrombosis and a 44% increase in ischemic TLR within 1 year of the procedure.
Several mechanisms may explain the poor outcomes after PCI of calcified lesions. First, it is well known that stent underexpansion is frequent in heavily calcified lesions and may increase the risk for restenosis and stent thrombosis (29) (30) (31) . As shown in the current report, the presence of calcifications was associated with an increase in the rate of ischemic events at 1 year, especially inside the first 30 days (Fig. 1, Online Fig. 1) , reflecting the detrimental impact of calcifications during stent implantation and resulting in an increase in acute and subacute stent failure. Second, difficulty in delivering stents may lead to structural device damage and, in the case of DES, may result in tearing or stripping the polymer, creating a prothrombotic/inflammatory nidus and/or promoting neointimal proliferation (7) . Third, a relationship between the severity of calcification and blood thrombogenicity has been reported. Borissoff et al. (32) demonstrated a positive independent association between greater in vivo thrombin generation and the presence and severity of coronary calcification. Similarly, Chirumamilla et al. (33) showed that patients treated with aspirin and clopidogrel in whom severe coronary calcification was versus was not visualized by intravascular ultrasound (IVUS) had higher platelet reactivity after PCI. Finally, several genetic loci have recently been associated with the development of vascular calcification and clinical events such as myocardial infarction (34, 35) . In the present study, PCI of calcified lesions was associated with suboptimal post-PCI results, including the more frequent occurrence of serious angiographic complications such as no reflow, dissection, and abrupt closure and lower final rates of Thrombolysis in Myocardial Infarction flow grade 3. PCI of calcified lesions in the setting of high platelet reactivity (as is typically present in ACS [36] ) may represent the perfect storm for both procedural complications as well as early and late stent thrombosis. Inclusive of the above, the presence of coronary calcification may represent a marker of poorer outcome and may not be the entire cause of worse outcome at follow-up. Although target lesion calcification was identified as an independent predictor of stent thrombosis and TLR, it is possible that even if technical advances were to obviate the negative consequences of calcification itself, the outcomes of these patients may still be worse.
Advanced age, male sex, hypertension, and STEMI presentation were independently associated with the presence of calcified target lesions in the current study. In prior studies of patients with stable coronary artery disease, in addition to older age, the extent of atherosclerosis and prior CABG were identified as independent predictors of calcification (37, 38) . This discrepancy may in part be explained by the different nature of the study populations (ACS vs. stable coronary disease). In addition, patients with chronic kidney disease (whether or not requiring dialysis) frequently have extensive coronary calcification, in part due to secondary hyperparathyroidism (39) . This population was underrepresented in our study population. Other covariates included in the models all-cause death: drug-eluting stent, male sex, hypertension, previous MI, previous PCI, previous CABG, number of attempted vessels, any left anterior descending artery (LAD) attempted, randomized to bivalirudin, extent of disease, lesion length, baseline RVD, baseline MLD, and modified American College of Cardiology (MACC)/American Heart Association >B2; cardiac death: drug-eluting stent, male sex, hypertension, previous MI, and number of attempted vessels; myocardial infarction: drug-eluting stent, age, male sex, diabetes, hypertension, any LAD attempted, randomized to bivalirudin, extent of disease, baseline RVD, baseline MLD, MACC >B2, and left ventricular ejection fraction (LVEF) (core laboratory assessed); ischemia-driven TLR: male sex, diabetes, current cigarette smoker, hypertension, previous MI, previous CABG, number of attempted vessels, any LAD attempted, baseline creatinine clearance <60 ml/min, baseline WBC count, randomized to bivalirudin, randomized to heparin, LVEF (core laboratory assessed), extent of disease, ostial lesion, lesion length, presence of thrombus, TIMI 0/1, baseline RVD, baseline degree stenosis, baseline MLD, MACC >B2, biomarker positive, and final no reflow; definite stent thrombosis: drug-eluting stent, male sex, diabetes, hypertension, previous MI, number of attempted vessels, randomized to bivalirudin, and extent of disease. Abbreviations as in Tables 2 and 3. JACC Vol. 63, No. 18, 2014
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Whether lesion decalcification prior to stent implantation can improve event-free survival of patients with calcified lesions is an area of ongoing investigation. Despite initial enthusiasm (40) (41) (42) (43) (44) , the use of rotational atherectomy prior to paclitaxel-eluting stent implantation in severely calcified lesions did not improve 9-month clinical or angiographic outcomes in the ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) randomized trial (45) . Although rotational atherectomy facilitated stent delivery and allowed a higher rate of immediate procedural success in this study, instent late loss at 9 months was greater after rotational atherectomy compared with lesion preparation with conventional balloon angioplasty alone prior to stenting (0.44 AE 0.58 mm vs. 0.31 AE 0.52 mm; p ¼ 0.04). These data are consistent with the results from studies in the balloon angioplasty and BMS eras, which reported higher rates of restenosis with rotational atherectomy (40, 43, (46) (47) (48) (49) (50) (51) (52) (53) . Greater neointimal hyperplasia with rotational atherectomy may be due to thermal injury, platelet activation, and medial injury (54, 55) . Moreover, use of rotational atherectomy in the setting of NSTEACS and STEMI in which thrombus is almost always present (even if angiographically unapparent) is considered an absolute contraindication. It is not therefore surprising that only 48 patients (0.7%) underwent rotational atherectomy in the present study. Ongoing and planned studies will determine whether the prognosis after PCI of calcified lesions can be improved by use of novel, less traumatic devices for plaque debulking (56) , perhaps coupled with current-generation metallic DES or bioresorbable vascular scaffolds, both of which are more potent than paclitaxel-eluting stents at reducing restenosis. Study limitations. The fact that an experienced independent angiographic core laboratory analyzed all 6,855 angiograms in the present report is a major strength, removing the element of operator variability and bias inherent in all prior studies. The large sample size of the present analysis also affords robust identification of predictors of target lesion calcification and adverse events. Independent adjudication of clinical events blinded to the angiographic findings is also notable. However, as an observational post-hoc analysis, the present analysis can only identify correlations, not prove causality. Despite adjustment for measured covariates, residual confounding may be present. The results of the present study should therefore be considered hypothesis generating. Even though the degree of calcification was assessed by experienced angiographic core laboratory technicians, the severity of calcification is underestimated by angiography compared with IVUS (57, 58) . The present study was underpowered to determine whether PCI of severely calcified as compared with moderately calcified target lesions was an independent predictor of adverse outcomes, as suggested in unadjusted analyses. Moreover, by arbitrary convention, only heavy calcification contributes to the SYNTAX score (59), a definition equivalent to that of severe calcification by QCA (18) . The present report suggests that in addition to heavy or severe calcification, moderate calcification, as assessed by an experienced angiographic core laboratory, also has significant impact on ischemic outcomes and therefore might be included in future risk models. Prospective validation of this concept is required. The studies pooled in the current report included implantation of approximately 20% of BMS and 80% firstgeneration DES. Given recent reports showing superior outcomes with second-generation DES (60), our findings may have been different had more contemporary stents been used. However, whether second-generation DES perform better in severely calcified lesions has yet to be demonstrated. IVUS was not required in the present study, and whether its use would improve risk stratification or treatment outcomes in calcified ACS lesions is unknown. Finally, the current report was limited to a 1-year follow-up after stent implantation. Longer-term patient assessment is required to determine if the adverse outcomes after PCI of calcified target lesions continue to accrue over time.
Conclusions
Target lesions in patients with NSTEACS and STEMI are frequently moderately or severely calcified, and PCI of such lesions was independently predictive of stent thrombosis and unplanned ischemia-driven TLR at 1 year, as compared with treatment of lesions with absent or only mild calcification. Novel approaches are urgently needed to improve outcomes of high-risk patients with ACS with calcified lesions undergoing PCI.
